On June 30 the CMS posted the first full year of disclosures under the Physician Payment Sunshine Act provision of the Affordable Care Act. According to the data posted to the CMS' Open Payments website, drug and medical-device companies paid teaching hospitals $543 million in general payments, which include speaking and consulting fees, gifts, travel and royalties for drugs based on research conducted by the providers. That latter category accounts for the vast majority of payments to City of Hope, which received far more than any of its peers. City of Hope received nearly $250 million in royalties from Genentech for its work on the science underlying the cancer drugs Avastin, Rituxan and Herceptin.
Blog: What drug and device companies paid teaching hospitals in 2014
Explore all of the 2014 payments to teaching hospitals disclosed by drug and device companies with the tool below.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.